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Abstract
Background: Coronary heart disease (CHD) mortality in England fell by approximately 6% every year between 2000 and
2007. However, rates fell differentially between social groups with inequalities actually widening. We sought to describe the
extent to which this reduction in CHD mortality was attributable to changes in either levels of risk factors or treatment
uptake, both across and within socioeconomic groups.
Methods and Findings: A widely used and replicated epidemiological model was used to synthesise estimates stratified by
age, gender, and area deprivation quintiles for the English population aged 25 and older between 2000 and 2007. Mortality
rates fell, with approximately 38,000 fewer CHD deaths in 2007. The model explained about 86% (95% uncertainty interval:
65%–107%) of this mortality fall. Decreases in major cardiovascular risk factors contributed approximately 34% (21%–47%)
to the overall decline in CHD mortality: ranging from about 44% (31%–61%) in the most deprived to 29% (16%–42%) in the
most affluent quintile. The biggest contribution came from a substantial fall in systolic blood pressure in the population not
on hypertension medication (29%; 18%–40%); more so in deprived (37%) than in affluent (25%) areas. Other risk factor
contributions were relatively modest across all social groups: total cholesterol (6%), smoking (3%), and physical activity (2%).
Furthermore, these benefits were partly negated by mortality increases attributable to rises in body mass index and
diabetes (29%;217% to23%), particularly in more deprived quintiles. Treatments accounted for approximately 52% (40%–
70%) of the mortality decline, equitably distributed across all social groups. Lipid reduction (14%), chronic angina treatment
(13%), and secondary prevention (11%) made the largest medical contributions.
Conclusions: The model suggests that approximately half the recent CHD mortality fall in England was attributable to
improved treatment uptake. This benefit occurred evenly across all social groups. However, opposing trends in major risk
factors meant that their net contribution amounted to just over a third of the CHD deaths averted; these also varied
substantially by socioeconomic group. Powerful and equitable evidence-based population-wide policy interventions exist;
these should now be urgently implemented to effectively tackle persistent inequalities.
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Introduction
Since the 1970s, coronary heart disease (CHD) mortality in
England has fallen by a remarkable 60%, with accelerated
reductions in annual death rates since 2000 [1]. However, CHD
remains the leading cause of mortality and is a major contributor
to social inequalities in premature mortality in England, as in the
USA [2,3]. Moreover, UK death rates have fallen faster in the
most socially advantaged groups compared to the most deprived
[1]. Thus, whilst absolute inequalities in mortality have fallen,
relative inequalities have increased over the last decade. Previous
country-level analyses have shown that about 50%–70% of the
dramatic falls in CHD mortality between 1980 and 2000 were
explained by improvements in modifiable risk factors (mainly
smoking, total cholesterol and blood pressure), with the remaining
30%–50% attributable to improved uptake of evidence-based
treatments [4–6]. However, so far no study has examined the
specific contribution of risk factors and medical treatments to the
underlying social differentials in CHD mortality falls.
The most recent study in the UK modelled CHD mortality
change in England and Wales between 1981 and 2000 [4]. Since
then several initiatives have been rolled out to improve the delivery
of health care in England. Notable among them include the
National Service Framework for CHD (2000) and the Qualities
and Outcome Framework (2004), which aim to monitor and
incentivise improvements in the quality of services provided for
CHD prevention, diagnosis, treatment, and rehabilitation [7,8]. In
addition, important population-wide public health measures to
reduce risk factors across the entire population were introduced.
These measures included the ban on tobacco advertising (2003);
comprehensive smoke-free legislation (2007), and voluntary
agreements to reduce salt and artificial trans-fats in processed
food [9,10]. Reducing health inequalities was at the heart of New
Labour’s health agenda when it came to office in 1997. However,
the target to reduce the inequality gap in life expectancy by 2010
was not met [11]. Furthermore, the potential effect of population-
wide interventions on reducing inequalities in CHD mortality
(when compared with individual treatments) remains unclear [12].
Thus although our analysis covers a relatively short period of
time, the period included a raft of measures specifically aimed to
improve outcomes and reduce social inequalities. We have
quantified the variation by socioeconomic circumstances (SEC)
in the relative contributions of modifiable population-level risk
factors and evidence-based individual treatments to the fall in
CHD mortality during the period 2000 to 2007. To do this we
have used the widely used and replicated IMPACT model,
substantially extending the model to capture socioeconomic
inequalities concealed within the overall national trends.
Methods
IMPACTSEC Model and Data Sources
IMPACT is an epidemiological model used to explain the
contributions of population-level risk factor changes (incidence
reduction) and uptake of evidence-based treatments (case fatality
reduction) to the change in CHD deaths between two points in
time. This deterministic, cell-based model has been described in
detail elsewhere [4,5]. The extended IMPACTSEC model included
all the major risk factors for CHD: smoking, systolic blood
pressure, total cholesterol, body mass index (BMI), diabetes,
physical inactivity, along with fruit and vegetable consumption;
plus all 45 medical and surgical treatments currently in use in nine
patient groups. The model included the total population of
England aged 25 y and over in 2000 and 2007.
Data sources specific to the England population were used to
construct the IMPACTSEC model. When several sources were
available, we chose the most up-to-date, representative dataset that
we could link to a small-area deprivation index. Population
estimates and CHD death counts (2000: ICD9 410–414; 2007:
ICD10 I20–I25) by sex, 5-y age bands to age 85+, and deprivation
quintile were obtained from the Office for National Statistics.
Emergency admissions for acute myocardial infarction were
extracted from Hospital Episode Statistics and supplemented with
data from the Myocardial Ischaemia National Audit Project to
disaggregate ST-elevated acute myocardial infarction and non–
ST-elevated acute coronary syndrome, and to apportion treatment
uptake to each group. For heart failure admissions, the National
Health Service (NHS) Heart Failure Survey was used to estimate
in-hospital treatment uptake. The General Practice Research
Database and the Health Survey for England provided data on
treatment uptake in the community. Risk factor trend data came
from the Health Survey for England.
Detailed information on the IMPACTSEC model, calculation
methods, and data sources are provided as supporting information
in Text S1.
Stratifying Data according to Socioeconomic
Circumstances
Only the Health Survey for England consistently recorded
individual socioeconomic position; but all data sources recorded
individual’s postcode of residence. We therefore used a measure of
relative area deprivation as a proxy indicator of the SECs of
individuals living in small areas (n=32,482; average population of
1,500). We used the Index of Multiple Deprivation 2007 [13] to
rank all lower super output areas in England in ascending order of
increasing deprivation and grouped them into equal quintiles.
Although scoring low on the deprivation index does not necessarily
equate to affluence, to assist readability we refer to quintile one as
‘‘most affluent’’ and quintile five as ‘‘most deprived.’’ On the basis
of postcode of residence, the data providers matched CHD deaths
and treated patients to their corresponding deprivation quintile
before releasing the data to us.
Deaths Prevented or Postponed
The total number of deaths prevented or postponed (DPPs) for
each deprivation quintile were calculated as the difference between
observed deaths in 2007 and expected deaths had age-, sex-, and
quintile- specific CHD mortality rates in 2000 remained unchanged.
DPPs explained by the model could be positive (i.e., deaths averted) or
negative (i.e., additional deaths in 2007 relative to 2000). Any
shortfalls between the DPPs explained by the model and the total
DPPs for each SEC quintile were assumed to reflect either imprecision
in ourmodel parameters or omission of other, unmeasured risk factors.
Mortality Reductions Attributable to Treatment Uptake
The treatment component of IMPACTSEC included nine
mutually exclusive CHD patient groups: ST-elevation myocardial
infarction; non–ST-elevation acute coronary syndrome; secondary
prevention post myocardial infarction; secondary prevention post
revascularisation; chronic stable coronary artery disease; heart
failure patients admitted to hospital; heart failure patients resident
in the community; persons in the community taking blood
pressure lowering medication; and persons in the community
taking lipid lowering treatment. A total of 45 patient-treatment
pairings were generated. To avoid double counting of patients
treated for two or more conditions within the year (e.g., heart
failure develops within 1 y after myocardial infarction in approx-
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imately 30% of survivors), we quantified overlaps between different
groups and made appropriate adjustments to construct distinct,
non-overlapping CHD patient subgroups (Text S1, Table N).
The numbers eligible for treatment, uptake of specific
treatment, 1-y case fatality rates, and relative risk reduction due
to treatment, all stratified by age, sex, and CHD patient
subgroups, were extracted from relevant data sources (Text S1,
Tables A, B, F, G, I, J). Disease prevalence and treatment uptake
were further stratified by deprivation quintiles.
The estimates of medication uptake in the community recorded
in our primary data sources were adjusted to reflect ordinary
clinical practice. We assumed that medication adherence (i.e., the
proportion of eligible patients actually taking therapeutically
effective levels of medication) was 100% among hospitalised
patients, 70% among symptomatic patients in the community, and
50% among asymptomatic patients in the community [5]. The
scale of the downward adjustment of uptake was assumed to
reasonably represent the combined effects of lower rates of
adherence in community settings and reduced population
effectiveness in routine health care settings compared to optimal
clinical trial conditions. Uncertainty in both of these input
variables—the actual uptake rates and the adjustment factor—
were included in the stochastic sensitivity analysis reported below.
Deaths prevented by each intervention were then calculated by
multiplying the numbers of patients in each diagnostic group by
the (adherence-adjusted) proportion of those patients who received
the treatment, the baseline case fatality rate, and the relative risk
reduction of that treatment. To estimate the cumulative effect of
relative risk reduction for patients on a combination of drug
therapies, we used the Mant and Hicks correction [14].
Many of the treatments were already widely used in 2000. The
net benefit of an intervention in 2007 was therefore calculated by
subtracting the expected number of deaths prevented if 2000
uptake rates had remained unchanged from the deaths prevented
using 2007 treatment uptake rates.
Mortality Reductions Attributable to Risk Factor Changes
We included seven risk factors in the model; both behavioural—
smoking, physical inactivity, fruit and vegetable consumption,
BMI—and physiological markers including systolic blood pressure,
total serum cholesterol, and diagnosed diabetes. To quantify the
mortality benefits of an absolute change in each specific risk factor
between 2000 and 2007, we used two approaches: a regression-
based approach for factors measured on a continuous scale (e.g.,
total blood cholesterol); and, a population-attributable risk fraction
approach for dichotomous variables such as diagnosed diabetes.
The independent regression coefficients of mortality benefit for a
unit change in mean risk factor were obtained from published
multivariate analyses (Text S1, Table I). Hence, the contribution
of each risk factor to deaths averted was then calculated as the
product of the deaths in 2000 (the base year), the absolute change
in risk factor, and the associated relative risk reduction. For binary
variables, we used relative risks from the most recent meta-
analyses and population cohort studies (Text S1, Table J).
CHD deaths are usually caused by multiple risk factors acting
simultaneously. It is therefore recommended that enumerating
mortality benefits from risk factor reductions should not use a
simple additive approach. Instead, the effects of risk factor changes
should be jointly estimated using the cumulative risk-reduction
approach. This can be stated in the equation:
Cumulative effect~1{((1{1)  (1{b)  (1{c)  :::(1{n)):
The cumulative effect of change in all risk factors over the study
period was calculated by age, sex, and deprivation quintile (see
Text S1, Section 1.3). The ratio of the cumulative effect to the
corresponding additive effect was then calculated, yielding 70
adjustment factors (Text S1, Table D). These adjustment factors
were used to scale down the additive DPPs for each risk factor.
These adjusted DPPs, summed over all seven risk factors, then
equalled the estimated total combined DPPs, capturing the
multiplicative net impact of positive and adverse changes in risk
factors. All risk factor DPPs quoted in the results tables refer to the
adjusted DPPs.
We assumed that there was no further synergy between the
treatment and risk-factor components of the model. Lag times
between the change in cardiovascular risk factor levels and change
in CHD mortality rates were assumed to be relatively rapid [15]
and were therefore not specifically modelled. Similar to economic
evaluation studies in health [16], 95% uncertainty intervals around
the model output (i.e., DPPs) were calculated using Monte Carlo
simulation. This calculation involved replacing all fixed input
parameters used in the model by appropriate probability
distributions, and repeatedly recalculating the model output with
values sampled from the defined input distributions (Text S1,
Table M). We used the EXCEL add-in Ersatz software (www.
epigear.com) to perform 1,000 runs to determine the 95%
uncertainty intervals of the DPPs (2.5th and 97.5th percentile
values corresponding to the lower and upper limits).
Results
Between 2000 and 2007, the age-standardised CHD mortality
rate in adults aged 25 y and over fell from 229 to 147 deaths per
100,000; a decline of 36% overall or 6.1% per year (Table 1). In
2007, there were 74,174 CHD deaths, 56% of these were in men.
Both death rates and the number of deaths were lowest in the most
affluent quintile and the pace of fall was also faster: decreasing by
6.7% per year compared to just 4.9% in the most deprived
quintile. Differentials in the rates of fall therefore widened relative
inequalities over the period.
Nationally, there were 38,070 fewer CHD deaths in 2007 than
if 2000 mortality rates had persisted, representing the ‘‘total’’
DPPs. Despite the slower annual rates of fall in the most deprived
quintile, their higher CHD mortality rates in the base year meant
that the number of DPPs by 2007 were fairly equally distributed:
about 6,560 fewer deaths in the most deprived quintile versus
7,355 in the most affluent (Table 1).
Overall, approximately half of the total CHD mortality fall
(19,780 fewer deaths or 52%; 95% uncertainly interval ranging
from 40% to 70%) was attributable to improvements in uptake of
medical and surgical treatments (Table 2). In contrast, population-
level risk factor changes accounted for approximately 12,990
(34%; 21%–47%) fewer deaths (Table 3). The model could not
explain some 14% of the overall mortality fall (i.e., a shortfall of
5,300 deaths) (Figure 1; Table 3). The contribution of medical
treatments to the deaths averted was very similar across all
quintiles, ranging from 50% in the most affluent quintile to 53% in
the most deprived (Table 4). But risk factor changes explained a
smaller proportion of deaths prevented in the most affluent
quintile compared with the most deprived (approximately 29%
versus 44%, respectively). As a result, about 21% of CHD deaths
prevented could not be explained by the model in the most
affluent quintile. The proportion not explained fell successively
with increasing deprivation to 3% of CHD deaths (190 deaths) not
explained in the most deprived quintile.
Explaining Social Inequalities in Falls in CHD Mortality Rates
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The most substantial contribution to deaths prevented by
treatments came from statin treatment for hyperlipidemia (14% of
the total mortality reduction, 5%–32%), management of chronic
stable coronary artery disease (13%; 10%–17%), and secondary
prevention following myocardial infarction or revascularisation
(11%; 8%–13%) (Table 2). Uptake rates of statins and angiotensin-
converting enzyme inhibitors (ACE inhibitors) or angiotensin
receptor blockers (ARB) more than doubled for secondary
prevention and the management of stable coronary artery disease
(Table 5). These two therapies together contributed some 6,340
DPPs (17%). In contrast, deaths averted due to changes in treatment
uptake in hospital-based patient groups were relatively modest:
contributing just 165 fewer deaths (0.5%; 21% to 3%) amongst
emergency admissions for infarction and unstable angina (ST
elevation myocardial infarction [STEMI] and non-ST elevation
acute coronary syndrome [NSTEACS], respectively). Improved
heart failure treatments in the community resulted in approximately
3,335 fewer deaths (9%; 7%–10%), with relatively modest gains
(250 fewer deaths) in hospitalised patients. Furthermore, there were
essentially no gradients in treatment uptake across deprivation
quintiles for either hospital treatment or drugs prescribed in the
community for secondary prevention and heart failure (Table 5).
Of the deaths prevented due to population-level risk factor
changes, the largest contribution came from the fall in systolic blood
pressure amongst those not on hypertensive medications (11,160
fewer deaths, or 29%; 18%–40%) (Table 3). On the other hand,
gains from hypertensive medication were modest (approximately
1,800 fewer deaths [5%; 2%–10%]) (Table 2). Blood pressure falls
were twice as high in women (5.4 mmHg versus 2.5 mmHg in men)
but were of a similar magnitude across all deprivation quintiles
(Table 6). Both in terms of absolute numbers and proportions, more
deaths were prevented because of blood pressure falls in the most
deprived quintile than in the most affluent (Tables 3 and 4).
In contrast, the benefits attributable to statin lowering of total
cholesterol levels were double those attributable to the fall in
cholesterol levels in the population not on treatment (approxi-
mately 5,300 versus 2,090 fewer deaths, respectively). Between
2000 and 2007, hyperlipidemia treatment increased nine-fold
across all social groups from 1% to 9% (Table 5). Total cholesterol
levels fell marginally more in women than men and by a similar
magnitude across deprivation quintiles (Table 6). Thus, while the
proportionate fall in deaths attributable to cholesterol reduction in
the general population was similar across quintiles, in absolute
terms more deaths were prevented in the most deprived quintiles
(Table 3).
Favourable trends in smoking, fruit and vegetable consumption,
and physical activity were modest; together only contributing
about 3,195 fewer deaths, or 8% (2%–18%) of the overall
mortality fall (Table 2). Smoking prevalence declined in men and
women by a similar amount (4%); however, there was a clear
social gradient with larger absolute falls in smoking prevalence in
more deprived quintiles (Table 6). Furthermore, levels of smoking
still remained twice as high in the most deprived compared to
affluent groups (Text S1, Table K). Physical inactivity fell more in
men (7%) than women (4%) across all deprivation quintiles;
however, three in four adults remained classed as inactive in every
quintile.
Mortality gains due to positive trends in smoking, fruit and
vegetable consumption, and physical activity risk factors were
negated by increases in BMI and diabetes (together contributing
3,460 additional deaths, equivalent to an 9% increase in mortality
(217% to 23%) (Table 3). Even over the relatively short period of
this analysis, the social gradient in diabetes became more
pronounced resulting in three times as many additional diabetes-
related deaths in the most deprived quintile compared with the
most affluent.
Table 1. Observed coronary heart disease deaths, age-standardised rates 2000 and 2007 and deaths prevented or postponed in
England and stratified by deprivation quintiles.
Adults Aged
25 and over England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived
Population (000s)
2000 33,952 6,972 7,035 6,939 6,678 6,329
2007 35,281 7,328 7,363 7,233 6,906 6,451
Observed deaths
2000 103,243 16,529 19,827 21,460 22,187 23,240
2007 74,174 12,312 14,444 15,347 15,676 16,395
Age-standardised rates
(per 100,000)
2000 229 177 199 222 257 306
2007 147 109 124 141 169 215
Annual percent fall 6.1 6.7 6.5 6.3 5.8 4.9
Expected deaths 2007
(had 2000 rates persisted)
112,244 19,665 22,669 23,696 23,260 22,953
DPP (Expected - observed
deaths, 2007)
38,070 7,353 8,225 8,349 7,584 6,558
Percent expected
deaths averted
33.9 37.4 36.3 35.2 32.6 28.6
Rates have been standardised to the European Union reference population aged 25 and over. Separate breakdowns for males and females are available in Text S1, Table
E.
IMD, index of multiple deprivation.
doi:10.1371/journal.pmed.1001237.t001
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Model Fit
The percentage unexplained by the model varied by age, sex, and
SECs. The model fit was generally good overall and in women and
men living in the most deprived areas (Text S1, Table L.3). However,
the fit was least good in affluent quintiles, with the 95% uncertainty
limits around the DPPs explained by the model (5,777; 4,134–7,420)
just overlapping with the number of observed DPPs (7,353). Model fit
was also better for women than men (see Text S1, Figure L.1).
Table 3. CHD deaths prevented or postponed due to changes in risk factor prevalence between 2000 and 2007 in England and
stratified by deprivation quintiles.
Risk Factors England: DPP By IMD: DPP
n Percent
Percent Lower
Limita
Percent Upper
Limita n Most Affluent n IMDQ2 n IMDQ3 n IMDQ4 n Most Deprived
Current smoking 1,040 2.7 0.1 5.6 93 148 189 242 368
Physical inactivity 600 1.6 0.8 2.3 91 109 119 130 155
Systolic blood
pressure, mmHgb
11,160 29.3 18.4 40.0 1,861 2,168 2,321 2,391 2,421
Total cholesterol,
mmol/lc
2,090 5.5 3.0 8.3 232 498 287 351 722
Fruit and
vegetable
consumption
1,555 4.1 1.1 8.3 305 334 342 301 273
BMI 2640 21.7 22.9 20.4 2111 2129 2135 2133 2135
Diabetes 22,820 27.4 212.6 22.5 2365 2438 2533 2577 2908
Total risk factors
contribution
12,990 34.1 21.1 47.3 2,107 2,690 2,591 2,704 2,896
Total treatment
contributiond
19,780 52.0 40.2 69.7 3,670 4,055 4,420 4,166 3,471
DPPs explained by
model
32,770 86.1 64.8 107.3 5,777 6,746 7,012 6,870 6,367
DPPs not
explained
5,300 13.9 1,576 1,479 1,337 714 191
Total DPPs 38,070 100 7,353 8,225 8,349 7,584 6,558
Subtotals for England (column 1) have been rounded to nearest 5.
aThe 95% uncertainty interval corresponds to the lower (2.5th percentile) and upper (97.5th percentile) limits of the uncertainty analysis.
bAfter subtracting DPPs due to hypertension treatment in primary prevention.
cAfter subtracting DPPs due to statin treatment in primary prevention.
dSee Table 2 for detailed breakdown by patient group and treatment type.
Abbreviations: IMD, index of multiple deprivation.
doi:10.1371/journal.pmed.1001237.t003
Figure 1. Proportion of coronary heart disease mortality decline attributable to treatment or risk factor changes, 2000–2007.
England overall and by socioeconomic quintile.
doi:10.1371/journal.pmed.1001237.g001
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Discussion
Between 2000 and 2007, English CHD mortality rates fell by an
impressive 36%, resulting in approximately 38,000 fewer CHD
deaths in 2007. However the relative mortality inequalities between
rich and poor persisted and even increased slightly over this period.
This study is the first, to our knowledge, to analyse the socioe-
conomic components concealed within the overall mortality
reductions attributable specifically to risk factor trends and to
evidence-based treatments. By using deprivation scores for area of
residence as a unified marker of SECs across all relevant large
databases of population health and health service use in England,
the study had adequate statistical size to quantify the impact of
changes in risk factors and treatments within socioeconomic groups,
even over a relatively short period of 7 y. Understanding these
recent trends, and their socially divergent trajectories, will be crucial
to planning the most effective and equitable future strategies to
prevent cardiovascular disease and reduce inequalities.
Main Findings
Approximately half the fall in CHD mortality was attributable
to increased medical therapies. These benefits largely reflected a
doubling of drug use for community patients with chronic disease
(who represent the largest CHD burden). In contrast, the
contribution of medical interventions in hospital was relatively
modest. Firstly, because the numbers of patients admitted to
hospital with acute disease were much smaller. Secondly, because
few new treatments were introduced after 2000 other than
clopidogrel and primary angioplasty. And thirdly, the uptake rates
for existing hospital-based treatments were already close to
maximum levels in 2000. The age-specific prevalence of CHD is
Table 4. Percentage distribution of deaths prevented of postponed by deprivation quintile.
Treatments by Patient
Groups; Risk Factors England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived
Treatments
STEMI 20.3 20.1 20.3 20.3 20.4 20.6
NSTEACS 0.8 0.8 0.7 0.7 0.7 1.0
Secondary prevention post MI 9.2 8.7 9.4 8.9 9.4 9.7
Secondary prevention
post revasc
1.5 1.5 1.5 1.5 1.5 1.7
Chronic stable CAD 12.7 11.6 12.2 12.2 13.3 14.6
Heart failure in the hospital 0.7 0.6 0.6 0.6 0.8 0.8
Heart failure in the community 8.8 7.7 8.4 8.8 9.4 9.8
Hypertension treatment 4.7 4.9 5.0 4.9 4.5 4.2
Hyperlipidemia
treatment (statins)
13.9 14.3 11.9 15.6 15.7 11.8
Total treatmentsa 52.0 49.9 49.3 52.9 54.9 52.9
Risk factors
Smoking 2.7 1.3 1.8 2.3 3.2 5.6
Diabetes 27.4 25.0 25.3 26.4 27.6 213.8
Physical inactivity 1.6 1.2 1.3 1.4 1.7 2.4
Systolic blood pressure, mmHg 29.3 25.3 26.4 27.8 31.5 36.9
Total cholesterol, mmol/l 5.5 3.2 6.1 3.4 4.6 11.0
BMI 21.7 21.5 21.6 21.6 21.7 22.1
Fruit and vegetable consumption 4.1 4.2 4.1 4.1 4.0 4.2
Total Risk Factorsa 34.1 28.7 32.7 31.0 35.7 44.2
DPPs explained by modela 86.1 78.6 82.0 84.0 90.6 97.1
DPPs not explained
by modela
13.9 21.4 18.0 16.0 9.4 2.9
DPP Countsa,b
DPPs explained by modela,b 32,770 5,777 6,746 7,012 6,870 6,367
- Due to treatment uptakeb 19,780 3,670 4,055 4,420 4,166 3,471
- Due to risk factor changeb 12,990 2,107 2,690 2,591 2,704 2,896
DPPs unexplained
by modela,b
5,300 1,576 1,479 1,337 714 191
Total DPPsa,b 38,070 7,353 8,225 8,349 7,584 6,558
aSub-totals (in rows).
bDPP counts for England (column 1) have been rounded to nearest 5. All counts are in italics.
Abbreviations: CAD, coronary artery disease; IMD, index of multiple deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial infarction; revasc,
revascularisation; STEMI, ST elevation myocardial infarction.
doi:10.1371/journal.pmed.1001237.t004
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Table 5. Percentage treatment uptake rates 2000 and 2007 for England and stratified by deprivation quintiles.
Treatment by
Patient Groups
Eligible
Patientsa England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived
2000b 2007b 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007
STEMI 20,700
Thrombolysis 77.2 56.7 79.4 58.6 77.9 59.5 75.4 57.1 76.2 56.0 77.4 52.5
Aspirin 93.6 96.0 93.6 96.6 94.7 96.3 93.1 95.4 93.2 95.6 93.4 96.4
B-blocker 71.3 70.3 74.8 70.9 72.3 69.1 71.0 69.8 69.6 69.5 69.9 72.4
ACE inhibitor or ARB 77.2 76.3 79.8 76.6 78.9 75.6 75.4 75.5 75.4 74.8 77.3 79.2
Clopidogrel 27.7 88.5 26.9 88.7 25.7 87.7 28.0 88.4 28.5 88.4 28.9 89.2
Primary PCI 3.9 23.7 2.9 24.2 3.4 21.8 3.8 23.3 4.3 24.5 4.8 24.8
Primary CABG 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.1
CPR in hospital 11.4 6.6 9.9 6.5 11.6 7.1 11.7 6.3 11.8 6.7 11.6 6.3
NSTEACS 91,285
Aspirin and heparin 64.0 79.7 67.1 79.7 65.0 80.3 66.7 79.9 65.7 80.2 57.9 78.8
Aspirin alone 24.2 12.8 21.5 13.5 23.9 12.3 21.5 12.7 23.5 12.6 28.9 13.1
PG IIB/IIIA 6.1 5.8 9.4 6.2 7.3 5.8 6.1 5.1 4.7 5.2 4.3 6.8
ACE inhibitor or ARB 66.0 73.2 68.6 73.1 64.5 72.2 65.9 72.5 64.3 72.7 67.0 75.0
B-blocker 63.2 67.6 66.1 68.2 62.7 67.7 63.5 66.7 61.7 66.3 62.8 69.2
Clopidogrel 44.3 86.6 43.5 87.1 44.2 86.9 42.3 86.8 45.6 85.9 45.4 86.3
CABG surgery 3.0 2.6 3.5 3.4 3.2 2.7 3.2 2.6 2.9 2.3 2.5 2.1
PCI 3.1 6.7 3.6 7.7 3.4 6.9 3.2 7.0 2.9 6.4 2.5 5.7
CPR in hospital 5.3 2.3 4.6 2.3 4.9 2.2 5.3 2.1 5.6 2.5 5.8 2.5
Secondary
prevention post
revascularisation
111,930
Aspirin 64.3 76.5 58.8 73.5 63.5 76.2 62.5 76.5 65.7 76.1 71.2 80.0
B-blocker 30.7 55.7 29.2 52.7 30.5 55.6 29.8 56.4 31.7 56.9 32.3 56.9
ACE inhibitor or ARB 30.1 64.2 30.8 63.9 29.2 63.0 29.5 63.9 30.9 63.4 30.5 67.1
Statin 58.2 84.5 61.7 85.1 58.2 84.6 56.3 83.9 56.3 84.8 58.7 84.2
Warfarin 7.4 6.7 7.9 7.2 7.3 6.6 6.7 6.5 7.1 7.1 7.9 6.1
Rehabilitation (post
CABG)
73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0 73.0
Rehabilitation (post
PTCA)
10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0 10.0 20.0
Secondary
prevention post MI
565,595
Aspirin 59.7 74.4 56.4 72.4 60.0 74.3 59.2 74.5 58.8 74.8 63.3 75.8
B-blocker 32.6 53.4 34.0 54.0 34.0 54.6 31.6 53.3 32.2 52.9 31.7 52.4
ACE inhibitor or ARB 31.3 62.0 32.3 62.6 32.5 62.3 31.0 61.6 30.6 61.2 30.5 62.5
Statin 37.1 77.4 39.8 77.9 39.5 77.8 35.9 76.6 34.7 76.6 36.2 78.1
Warfarin 6.6 8.1 7.7 8.3 6.7 8.9 6.5 7.9 6.2 7.7 6.2 7.6
Rehabilitation 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0
Chronic stable CAD 984,805
Aspirin in community 42.9 62.4 38.7 57.2 42.6 61.4 44.7 64.3 42.9 63.4 45.0 65.3
Statin in community 23.9 66.2 25.4 63.4 24.2 65.4 23.7 66.5 23.0 66.3 23.3 69.2
ACE inhibitor or ARB 19.8 45.7 19.9 45.1 19.0 45.5 20.5 45.8 20.1 45.5 19.7 46.5
CABG surgery 8.7 9.6 8.8 9.8 8.7 9.7 9.6 10.3 8.7 9.7 7.7 8.8
Heart failure -
hospital
24,625
ACE inhibitor 53.2 59.1 51.8 57.6 52.1 57.9 52.7 58.6 53.4 59.4 55.2 61.4
B-blocker 25.4 28.2 24.3 27.0 24.5 27.2 25.0 27.8 25.6 28.5 27.1 30.1
Spironolactone 20.7 22.9 19.8 22.0 20.0 22.3 20.4 22.7 20.8 23.1 21.8 24.3
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socially graded. With similar levels of uptake of treatments across
socioeconomic quintiles in both base and final years, this meant
that the benefits of increased treatment were distributed remark-
ably evenly across social groups, which suggests a fairly equitable
distribution of therapies across the NHS.
Reductions in major cardiovascular risk factors explained over
two-fifths of the fall in CHD mortality (43%). However, the net
benefit was much smaller (approximately 34%) because adverse
trends in BMI and diabetes potentially increased mortality by
some 9%.
The single largest contribution to the overall CHD mortality
decrease came from population falls in blood pressure [17] with
relatively small gains from hypertension therapies. Furthermore,
reductions were similar across social groups. This is therefore
entirely consistent with recent UK population-wide reductions in
salt intake [18], and with recent encouraging trends in other
wealthy counties [19].
Small increases in fruit and vegetable consumption and physical
activity were seen across all social groups. Furthermore, moderate
declines in smoking levels were actually greater in deprived areas.
This may reflect the benefit of cumulative tobacco control policies
since 2000, reinforced by the targeting of cessation services in
deprived areas [20].
However, after excluding the effect of statin therapy, the decline
in cholesterol levels in the wider population was modest. This
finding may well reflect a failure to implement more effective
dietary policies [21]. Particularly worrying was the approximately
3,500 additional deaths attributable to the continuing rises in
diabetes and BMI. This number is consistent with recent Foresight
analyses and represents a further warning to policy makers [22].
The absolute gap in CHD mortality between the most affluent
and most deprived groups narrowed over the period of our study,
however relative inequalities widened. This was unlikely to be due to
differential treatment of diagnosed patients because levels of uptake
of evidence-based therapies were similar for all groups. The pace of
fall in mortality in the most affluent groups was faster; but changes
in risk factor levels could not explain about 20% of this fall. By
contrast, in the most deprived quintile, changes in risk factor levels
explained almost all of the remaining CHD mortality fall after
accounting for deaths averted due to increase in treatment uptake
rates. Perhaps the most likely explanation for this difference is a
social gradient in effect modification. Thus, the current model
assumed that the mortality decrease per unit change in risk factor
was similar across deprivation quintiles. However, the benefits of a
specific decrease in blood pressure or cholesterol may be
disproportionately higher in more affluent groups, perhaps reflect-
ing synergy with other positive trends [23]. A recent cohort analysis
found that even if four classic risk factors—blood pressure,
cholesterol, smoking, and diabetes—were to be completely elimi-
nated in middle-aged men, relative inequalities in CHD mortality
between those in low and high employment grades would persist
despite a 70% reduction in absolute mortality differences [24].
Furthermore we do not have many estimates of the cumulative
benefit associated with a lifetime of low risk. For example, the
Finnish Public Sector Study found that a marked socioeconomic
gradient in absolute risk of CHD mortality persisted even in a low-
risk subgroup that had never smoked, were not obese or physically
inactive, and who consumed moderate amounts of alcohol [25].
Alternative explanations for the fraction of the mortality fall
unexplained by the model include the possible omission of more
‘‘upstream’’ risks such as psychosocial stress, which might
differentially benefit affluent groups [23,26]. Differential levels of
adherence to prescribed medications may also play a role;
however, this is a relatively under-researched area without clear-
cut evidence to support or refute the existence of systematic social
gradients [27–29]. We also tested the impact of varying adherence
rates differentially on the DPPs explained. However, varying
adherence rates in this way had a limited effect on reducing the
gradient in the proportion unexplained. Finally, measurement
error may contribute; Health Survey estimates of risk factor trends
by deprivation quintiles may lack precision because of small
samples and differential response rates.
Comparisons with Other UK and International Studies
Compared with previous IMPACT analyses from a baseline of
the 1980s [4,5,30–33], models of more recent changes, for
Table 5. Cont.
Treatment by
Patient Groups
Eligible
Patientsa England Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived
2000b 2007b 2000 2007 2000 2007 2000 2007 2000 2007 2000 2007
Aspirin 59.2 73.9 56.6 71.9 59.8 73.3 58.6 74.1 58.1 75.3 62.2 74.4
Heart failure -
community
172,770
ACE inhibitor or ARB 45.6 68.9 48.2 70.2 44.5 69.3 43.4 67.8 45.9 69.2 46.6 68.4
B-blocker 10.4 34.2 10.7 35.1 11.2 34.6 10.8 34.9 9.4 34.2 10.1 32.4
Spironolactone 3.9 14.5 4.3 14.7 3.9 14.9 3.6 13.0 3.9 15.1 4.0 14.9
Aspirin 38.1 50.4 37.9 46.3 38.3 49.9 37.3 50.3 37.0 51.8 40.0 52.7
Hypertension
treatment
35,280,845 8.3 13.5 8.3 14.0 8.2 13.8 8.6 13.9 8.2 13.0 8.3 12.7
Hyperlipidemia
treatment
35,280,845 1.1 9.0 1.0 7.9 1.1 8.5 1.1 9.1 1.4 10.3 1.3 9.1
The overall treatment uptake rate is a weighted average over all age groups 25+ and both sexes.
aEligible patient numbers rounded to nearest 5.
bSub-totals (in rows) for CHD patient groups.
Abbreviations: B-blocker: beta-blocker; CABG: coronary artery bypass graft; CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; IMD, index of multiple
deprivation; NSTEACS, non-ST elevation acute coronary syndrome; MI, myocardial infarction; PCI, percutaneous coronary intervention; PG, platelet glycoprotein; PTCA,
percutaneous transluminal coronary angioplasty; STEMI, ST elevation myocardial infarction.
doi:10.1371/journal.pmed.1001237.t005
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example in Ontario [6], demonstrate the growing relative
contribution from improved treatments to reductions in CHD
mortality. However, country-specific proportions attributable to
risk factors or treatments are relative to the scale of the decline,
and hence potentially misleading. Thus, although Nordic countries
possess uniformly good health services, their larger absolute falls in
coronary mortality mainly reflect particularly impressive decreases
in major risk factors, mainly cholesterol, blood pressure and
smoking, and smaller increases in obesity and diabetes [33,34].
Strengths and Limitations of This Study
The IMPACT model has been replicated and validated in
diverse national populations. This is the first IMPACT study to
quantify the socioeconomic components of the contributions of
changes in treatment and risk factors to falls in coronary mortality.
The main datasets used are reasonably representative of the
socioeconomic distribution of the English population and large
enough for reasonably accurate estimates of socioeconomic
change.
However, a number of limitations should also be acknowledged.
These include the use of area-level categorisation of SECs.
However, area deprivation correlates well with individual socio-
economic position and may also help to capture the contextual
effects of living conditions [35,36].
Approximately 14% of the CHD mortality fall was not
explained by the model and the uncertainty analysis also
produced wide limits in the percentage explained (86%; 65%–
107%). The model fit was also less good in men in affluent areas,
as discussed earlier. However, the model fit was generally good
overall and in women and in men living in the most deprived
areas. As with all models attempting to capture complex and
interacting changes, it remains possible that there were additional
(unquantifiable) sources of error not captured by the uncertainty
analysis.
Conclusions and Implications for Future Prevention
Policies and Strategies
Approximately half of the recent substantial CHD mortality fall
in England was attributable to medical therapies. Benefits were
relatively even across social groups. These findings are consistent
with equitable service delivery across the NHS. Treatment uptake
in hospitals was close to maximum levels over the entire period,
while follow-up treatment of cardiovascular patients in the
community substantially improved and was equitable. This
suggests the Qualities and Outcome Framework that was being
implemented in general practice during the study period was an
effective incentive for improving uptake overall [37].
Table 6. Absolute change in risk factor levels between 2000 and 2007 for England and stratified by deprivation quintiles and sex.
Risk Factors Overall Levels Absolute Change in Percentage Points, 2000–2007
2000 2007 Englandc Most Affluent IMDQ2 IMDQ3 IMDQ4 Most Deprived
Smoking prevalence (%)
Male 27.2 23.6 23.7 22.6 23.1 23.6 24.1 24.8
Female 23.4 19.9 23.5 22.5 23.0 23.4 24.0 24.6
Diabetes prevalence (%)
Male 3.7 6.5 2.8 2.4 2.7 2.8 2.6 3.6
Female 2.9 4.8 1.9 1.6 1.4 1.6 2.1 2.8
Physical inactivity (%)
Male 80.9 74.0 26.9 26.9 26.7 26.8 26.9 27.2
Female 82.4 78.1 24.3 24.3 24.2 24.2 24.2 24.4
Systolic blood pressure
(mmHg)
Male 133.1 130.6 22.5 22.6 22.6 22.5 22.5 22.4
Female 131.0 125.6 25.4 25.3 25.5 25.5 25.5 25.5
Total cholesterol (mmol/l)
Male 5.6 5.4 20.1 20.2 20.2 20.2 20.1 20.1
Female 5.7 5.5 20.2 20.2 20.2 20.2 20.2 20.2
BMI (kg/m2)
Male 27.3 27.7 0.4 0.4 0.4 0.4 0.3 0.3
Female 26.9 27.2 0.2 0.2 0.2 0.2 0.2 0.3
Fruit and vegetable
consumption (portions
per day)
Male 3.4 3.7 0.4 0.4 0.4 0.4 0.4 0.3
Female 3.6 4.0 0.4 0.4 0.4 0.4 0.4 0.4
See Text S1, Table K for weighted averages of risk factor levels for each deprivation quintile, 2000 and 2007.
aEngland average weighted by 2007 population distribution in 10-y age bands.
IMD, index of multiple deprivation.
doi:10.1371/journal.pmed.1001237.t006
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However, the net gains from risk factor improvements were
small, reflecting modest recent decreases in powerful cardiovascular
risk factors such as smoking and cholesterol, and further eroded by
continuing rises in BMI and diabetes. This throws a spotlight on
recent UK policies for salt reduction and tobacco control (relatively
effective) and healthier diets (relatively neglected). Elsewhere, the
successful introduction of effective, powerful, rapid, and cost-saving
policy interventions have achieved substantial reductions in the
saturated fat, trans-fats, sugars, and calories hidden in processed
food, takeaways, and sweetened drinks [21,37,38]. Mandatory
interventions involving legislation, regulation, taxation, or subsidies
consistently appear more effective and cost saving than voluntary
schemes [19,39,40]. They also tend to be equitable [12] and
surprisingly rapid [15,38]. The UK now has an equally pressing
need for population-wide policy interventions to effectively tackle
persistent inequalities in cardiovascular mortality.
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Editors’ Summary
Background. Coronary heart disease is a chronic medical
condition in which the blood vessels supplying the heart
muscle become narrowed or even blocked by fatty deposits
on the inner linings of the blood vessels—a process known
as arthrosclerosis; this restricts blood flow to the heart, and if
the blood vessels completely occlude, it may cause a heart
attack. Lifestyle behaviors, such as unhealthy diets high in
saturated fat, smoking, and physical inactivity, are the main
risk factors for coronary heart disease, so efforts to reduce
this condition are directed towards these factors. Global
rates of coronary heart disease are increasing and the World
Health Organization estimates that by 2030, it will be the
biggest cause of death worldwide. However, in high-income
countries, such as England, deaths due to coronary heart
disease have actually fallen substantially over the past few
decades with an accelerated reduction in annual death rates
since 2000.
Why Was This Study Done? Socioeconomic factors play
an important role in chronic diseases such as coronary heart
disease, with mortality rates almost twice as high in deprived
than affluent areas. However, the potential effect of
population-wide interventions on reducing inequalities in
deaths from coronary heart disease remains unclear. So in
this study, the researchers investigated the role of behavioral
(changing lifestyle) and medical (treatments) management
of coronary heart disease that contributed to the decrease in
deaths in England for the period 2000–2007, within and
between socioeconomic groups.
What Did the Researchers Do and Find? The researchers
used a well-known, tried and tested epidemiological model
(IMPACT) but adapted it to include socioeconomic inequal-
ities to analyze the total population of England aged 25 and
older in 2000 and in 2007. The researchers included all the
major risk factors for coronary heart disease plus 45 current
medical and surgical treatments in their model. They used
the Index of Multiple Deprivation 2007 as a proxy indicator
of socioeconomic circumstances of residents in neighbor-
hoods. Using the postal code of residence, the researchers
matched deaths from, and patients treated for, coronary
heart disease to the corresponding deprivation category
(quintile). Changes in risk factor levels in each quintile were
also calculated using the Health Survey for England. Using
their model, the researchers calculated the total number of
deaths prevented or postponed for each deprivation quintile
by measuring the difference between observed deaths in
2007 and expected deaths based on 2000 data, if age, sex,
and deprivation quintile death rates had remained the same.
The researchers found that between 2000 and 2007, death
rates from coronary heart disease fell from 229 to 147 deaths
per 100,000—a decrease of 36%. Both death rates and the
number of deaths were lowest in the most affluent quintile
and the pace of fall was also faster, decreasing by 6.7% per
year compared to just 4.9% in the most deprived quintile.
Furthermore, the researchers found that overall, about half
of the decrease in death rates was attributable to improve-
ments in uptake of medical and surgical treatments. The
contribution of medical treatments to the deaths averted
was very similar across all quintiles, ranging from 50% in the
most affluent quintile to 53% in the most deprived. Risk
factor changes accounted for approximately a third fewer
deaths in 2007 than occurred in 2000, but were responsible
for a smaller proportion of deaths prevented in the most
affluent quintile compared with the most deprived (approx-
imately 29% versus 44%, respectively). However, the benefits
of improvements in blood pressure, cholesterol, smoking,
and physical activity were partly negated by rises in body
mass index and diabetes, particularly in more deprived
quintiles.
What Do These Findings Mean? These findings suggest
that approximately half the recent substantial fall in deaths
from coronary heart disease in England was attributable to
improved treatment uptake across all social groups; this is
consistent with equitable service delivery across the UK’s
National Health Service. However, opposing trends in major
risk factors, which varied substantially by socioeconomic
group, meant that their net contribution accounted for just a
third of deaths averted. Other countries have implemented
effective, evidence-based interventions to tackle lifestyle risk
factors; the most powerful measures involve legislation,
regulation, taxation, or subsidies, all of which tend to be
equitable. Such measures should be urgently implemented
in England to effectively tackle persistent inequalities in
deaths due to coronary heart disease.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001237.
N The World Health Organization has information about the
global statistics of coronary heart disease
N The National Heart Lung and Blood Institute provides a
patient-friendly description of coronary heart disease
N The National Heart Forum is the leading UK organization
facilitating the prevention of coronary heart disease and
other chronic diseases
N The British Heart Foundation supports research and
promotes preventative activity
N Heart of Mersey is the UK’s largest regional organization
promoting the prevention of coronary heart disease and
other chronic diseases
N More information about the social determinants of health
is available from WHO
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